Safety differentiates anti-IL-23p19 treatments from other biologic treatments. There is a theoretical risk of infection and malignancy with the use of any immunosuppressant, including biologics. However, compared with the inhibition of other inflammatory cytokines, IL-23 targeting may only minimally impair the ability to generate a proper immune response.<unk>  has proven to be a well-tolerated treatment in the long term. The most common (≥ 1%) side effects associated with<unk>  treatment are upper respiratory infections, headache, gastroenteritis, nausea, diarrhoea, injection site pain, and back pain. In the reSURFACE 1 and 2 clinical trials, the overall incidence of side effects was low and comparable to placebo. Specifically, the incidence of severe infections, malignancies, and major adverse cardiovascular events was low and similar to that of placebo and etanercept treatment groups.
Tildrakizumab
Brolucizumab
Risankizumab
Mogamulizumab
Etaracizumab
Caplacizumab
Ixekizumab
Crizanlizumab